<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology of bisphosphonates</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology of bisphosphonates</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacology of bisphosphonates</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold N Rosen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic review provides an overview of the pharmacology of the bisphosphonates and of the differences between the preparations that are either currently available or undergoing clinical testing. Because bisphosphonates inhibit bone resorption, they are used in the treatment of hypercalcemia, osteoporosis, metastatic bone disease, and Paget disease. These uses are discussed separately.</p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY</span><span class="headingEndMark"> — </span>Bisphosphonates all have in common the P-C-P structure, which is similar to the P-O-P structure of native pyrophosphate (<a class="graphic graphic_figure graphicRef65606" href="/d/graphic/65606.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. Bisphosphonates differ from each other only at the two "R" groups in the accompanying figures (<a class="graphic graphic_figure graphicRef65606" href="/d/graphic/65606.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef82089" href="/d/graphic/82089.html" rel="external">figure 2</a>). <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">Alendronate</a>, neridronate, <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>, <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a>, <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>, and <a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a> have a nitrogen group and are called nitrogen-containing bisphosphonates, in contrast with <a class="drug drug_general" data-topicid="8426" href="/d/drug information/8426.html" rel="external">etidronate</a> and tiludronate, which do not (<a class="graphic graphic_figure graphicRef82089" href="/d/graphic/82089.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H3"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>The bisphosphonates inhibit osteoclastic bone resorption via a mechanism that differs from that of other antiresorptive agents [<a href="#rid2">2-4</a>]. Bisphosphonates attach to hydroxyapatite binding sites on bony surfaces, especially surfaces undergoing active resorption. When osteoclasts begin to resorb bone that is impregnated with bisphosphonate, the bisphosphonate released during resorption impairs the ability of the osteoclasts to form the ruffled border, to adhere to the bony surface, and to produce the protons necessary for continued bone resorption [<a href="#rid2">2,3,5</a>]. Bisphosphonates also reduce osteoclast activity by decreasing osteoclast progenitor development and recruitment and by promoting osteoclast apoptosis [<a href="#rid6">6</a>].</p><p>In addition to their inhibitory effect on osteoclasts, bisphosphonates appear to have a beneficial effect on osteoblasts. In a murine model of glucocorticoid-induced osteoporosis, bisphosphonates prevented osteocyte and osteoblast apoptosis [<a href="#rid7">7</a>]. The mechanism of this effect involves connexin 43, a gap junction protein that facilitates activation of protein kinases. This anti-apoptotic effect, however, probably does not contribute significantly to the anti-osteoporotic efficacy of bisphosphonates, above their potent antiresorptive actions.</p><p>Bone formation is often reduced by bisphosphonates, which is probably an indirect effect of inhibition of bone resorption. In normal bone remodeling, bone resorption and formation are coupled. Changes in resorption drive formation, so when bone resorption decreases, bone formation also decreases. (See  <a class="medical medical_review" href="/d/html/2053.html" rel="external">"Normal skeletal development and regulation of bone formation and resorption", section on 'Remodeling'</a>.)</p><p>Despite their structural similarities, there are important differences among the bisphosphonates in potency and toxicity. The nitrogen-containing bisphosphonates (<a class="drug drug_general" data-topicid="9902" href="/d/drug information/9902.html" rel="external">zoledronic acid</a>, <a class="drug drug_general" data-topicid="10242" href="/d/drug information/10242.html" rel="external">risedronate</a>, <a class="drug drug_general" data-topicid="8887" href="/d/drug information/8887.html" rel="external">ibandronate</a>, <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a>, neridronate, and <a class="drug drug_general" data-topicid="9736" href="/d/drug information/9736.html" rel="external">pamidronate</a>) are more potent inhibitors of bone resorption than the simple bisphosphonates (<a class="drug drug_general" data-topicid="8426" href="/d/drug information/8426.html" rel="external">etidronate</a>, <a class="drug drug_general" data-topicid="8774" href="/d/drug information/8774.html" rel="external">clodronate</a>, tiludronate) (<a class="graphic graphic_table graphicRef50479" href="/d/graphic/50479.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H4"><span class="h3">Nitrogen-containing bisphosphonates</span><span class="headingEndMark"> — </span>The nitrogen-containing bisphosphonates act primarily by inhibiting the enzyme farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway (cholesterol biosynthetic pathway). Inhibition of FPP synthase disrupts protein prenylation, which creates cytoskeletal abnormalities in the osteoclast, promotes detachment of the osteoclast from the bone perimeter, and leads to reduced bone resorption [<a href="#rid8">8-11</a>]. The relative antiresorptive potency of the individual nitrogen-containing bisphosphonates is related to the potency with which they inhibit FPP synthase [<a href="#rid12">12</a>].</p><p>When FPP synthase is disrupted, there is an accumulation of a precursor, isopentenyl pyrophosphate (IPP), which can bind to a receptor and cause the release of tumor necrosis factor (TNF)-alpha. This pathway, leading to the production of TNF-alpha, is hypothesized to cause the acute-phase reaction, a well-recognized side effect of intravenous bisphosphonates [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Flu-like symptoms'</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Simple bisphosphonates</span><span class="headingEndMark"> — </span>Bisphosphonates that do not contain nitrogen have a different mode of action. They are metabolized by osteoclasts to metabolites that exchange with the terminal pyrophosphate moiety of adenosine triphosphate (ATP), resulting in an ATP that cannot be used as a source of energy. The osteoclasts then undergo apoptosis [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Mineralization</span><span class="headingEndMark"> — </span>Pyrophosphate is an important inhibitor of mineralization, and it is prevented from entering the bone by alkaline phosphatase in the bone lining cells. The bisphosphonates, which have a structure similar to native pyrophosphate, have a strong affinity to mineral, and they are not cleaved by the alkaline phosphatase. Thus, they can inhibit mineralization.</p><p>However, there are differences among the bisphosphonates in their potential to inhibit mineralization and cause osteomalacia. <a class="drug drug_general" data-topicid="8426" href="/d/drug information/8426.html" rel="external">Etidronate</a>, as an example, inhibits bone resorption and mineralization at the same concentration. This unfavorable therapeutic index (1:1) is the reason why etidronate is used infrequently for the treatment of osteoporosis. In comparison, the dose of nitrogen-containing bisphosphonates that inhibits bone mineralization is 1000 times the dose that inhibits bone resorption. One study of transiliac bone biopsies 24 or 36 months after the start of <a class="drug drug_general" data-topicid="9427" href="/d/drug information/9427.html" rel="external">alendronate</a> treatment confirmed that bone mineralization was normal and trabecular bone resorption was markedly decreased [<a href="#rid14">14</a>]. Thus, the circulating concentrations of the nitrogen-containing bisphosphonates currently in use inhibit skeletal resorption but do not cause osteomalacia [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>Bisphosphonates are poorly absorbed orally (1 to 5 percent of an oral dose), and absorption is best when they are given on an empty stomach [<a href="#rid15">15</a>]. We recommend that oral bisphosphonates be taken only with water and that the patient then wait at least 30 minutes before ingesting food or other medications. More convenient oral dosing regimens, eg, once weekly or monthly, are available and are preferred by most patients. Intravenous preparations, which require even less frequent dosing, are also available for those unable to tolerate oral regimens.</p><p>Approximately 70 percent of the absorbed bisphosphonate is cleared by the kidney, and the remaining 30 percent is taken up by bone. Relative bone uptake is increased in conditions of high bone turnover, with less of the drug being excreted by the kidneys. Conversely, uptake in bone is reduced and kidney excretion is increased when turnover is low [<a href="#rid16">16</a>]. Bisphosphonates are cleared rapidly from the plasma (half-life is approximately one hour) but may persist in bone for the patient's lifetime [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL USE AND ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Bisphosphonates can be given to patients with any condition characterized by excessive bone resorption, such as osteoporosis, hypercalcemia of any cause, metastatic bone disease, and Paget disease. They are also used to treat heritable skeletal disorders in children, such as osteogenesis imperfecta. The clinical efficacy and adverse effects of bisphosphonates are discussed in greater detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2030.html" rel="external">"Bisphosphonate therapy for the treatment of osteoporosis", section on 'Practical management issues'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia", section on 'Choice of antiresorptive agent: Bisphosphonates'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/776.html" rel="external">"Use of osteoclast inhibitors in early breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5596.html" rel="external">"Treatment of Paget disease of bone"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy"</a>.)</p><p></p><p class="headingAnchor" id="H8538676"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Bisphosphonates potently inhibit bone resorption by reducing osteoclast number and function. The nitrogen-containing bisphosphonates are more potent than the simple bisphosphonates. (See <a class="local">'Pharmacology'</a> above and <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nitrogen-containing bisphosphonates</strong> – The nitrogen-containing bisphosphonates work primarily by inhibiting the enzyme farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway (cholesterol biosynthetic pathway), thereby disrupting protein prenylation, which creates cytoskeletal abnormalities in the osteoclast, promotes detachment of the osteoclast from the bone perimeter, and leads to reduced bone resorption. Antiresorptive potency is directly related to potency for inhibition of FFP synthase. (See <a class="local">'Nitrogen-containing bisphosphonates'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Simple bisphosphonates</strong> – Simple bisphosphonates have a different mechanism of action. They are metabolized by osteoclasts to metabolites that exchange with the terminal pyrophosphate moiety of adenosine triphosphate (ATP), resulting in an ATP that cannot be used as a source of energy. The osteoclasts then undergo apoptosis. (See <a class="local">'Simple bisphosphonates'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong> – Bisphosphonates are poorly absorbed orally (1 to 5 percent of an oral dose), but absorption is best when they are given on an empty stomach. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – Bisphosphonates may be clinically useful in any condition characterized by excessive bone resorption. (See <a class="local">'Clinical use and adverse effects'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83:1032.</a></li><li><a class="nounderline abstract_t">Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97:2692.</a></li><li><a class="nounderline abstract_t">Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88:2095.</a></li><li><a class="nounderline abstract_t">Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80.</a></li><li><a class="nounderline abstract_t">Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998; 63:230.</a></li><li><a class="nounderline abstract_t">Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478.</a></li><li><a class="nounderline abstract_t">Plotkin LI, Lezcano V, Thostenson J, et al. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008; 23:1712.</a></li><li><a class="nounderline abstract_t">van beek E, Löwik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999; 14:722.</a></li><li><a class="nounderline abstract_t">Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004; 75:451.</a></li><li><a class="nounderline abstract_t">Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007; 119 Suppl 2:S150.</a></li><li><a class="nounderline abstract_t">Dunford JE. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Curr Pharm Des 2010; 16:2961.</a></li><li><a class="nounderline abstract_t">Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235.</a></li><li><a class="nounderline abstract_t">Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19:733.</a></li><li><a class="nounderline abstract_t">Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100:1475.</a></li><li class="breakAll">Fleisch H. Pharmacokinetics. In: Bisphosphonates in Bone Disease: From the Laboratory to the Patient, University of Berne, Berne, Switzerland 1993. p.50.</li><li><a class="nounderline abstract_t">Reid IR, Horne AM, Mihov B, Gamble GD. Bone Loss After Denosumab: Only Partial Protection with Zoledronate. Calcif Tissue Int 2017; 101:371.</a></li></ol></div><div id="topicVersionRevision">Topic 2024 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775204" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bisphosphonates: mechanism of action and role in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675678" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bisphosphonates: mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1661297" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9494781" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bisphosphonates: mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9701627" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8686503" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18597631" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10320520" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332174" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332236" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bisphosphonates: mode of action and pharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20722615" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160603" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18214569" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294113" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294113" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28500448" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bone Loss After Denosumab: Only Partial Protection with Zoledronate.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
